Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com

Investors: Peter Vozzo Westwicke Partners 443-213-0505 peter.vozzo@westwicke.com

Grafico Azioni Adamas Pharmaceuticals (NASDAQ:ADMS)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Adamas Pharmaceuticals
Grafico Azioni Adamas Pharmaceuticals (NASDAQ:ADMS)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Adamas Pharmaceuticals